Consolidated revenues were posted at ₹38.4 billion, year-on-year growth of nine per cent
Dr Reddy’s Laboratories announced its unaudited consolidated financial results for the quarter and nine months ended December 31, 2014 under International Financial Reporting Standards (IFRS).
Consolidated revenues were posted at ₹38.4 billion, year-on-year growth of nine per cent. Revenues from the Global Generics (GG) segment at ₹31.7 billion, YoY growth of eight per cent. Revenues from the Pharmaceutical Services and Active Ingredients (PSAI) segment at ₹6.1 billion. Y-o-Y growth of 21 per cent. Gross profit margin at 58.2 per cent in Q3FY15 versus 60.5 per cent as in Q3 FY 14.
Research & Development (R&D) expenses were posted at ₹4.3 billion, 11.2 per cent to revenues versus 8.4 per cent to revenues as in Q3 FY14.
Selling, general and administrative (SG&A) expenses were at ₹11.2 billion, 29 per cent to revenues. EBITDA was at ₹10.5 billion, 27 per cent to revenues. Profit after tax was at ₹5.7 billion, 15 per cent to revenues.
During the quarter the company launched 13 new generic products, filed 18 new product registrations and 14 DMFs globally.
Comments are closed.